-
2024-518437-28-00
5
Sickle cell disease
-
2024-519298-21-00
5
Cancer-Associated Thrombosis (CAT).
-
2024-519504-27-00
5
Relapsed Refractory Multiple Myeloma
-
2024-519753-11-00
4
Resectable borderline pancreatic adenocarcinoma
-
2024-520414-21-00
5
Adult patients with a LVOS with large core within 9 hours of symptoms
-
2025-520632-42-00
5
axial or predominantly axial SpA with or without psoriasis
-
2025-520976-25-00
4
Relapsed/refractory multiple myeloma
-
2025-521090-14-00
4
Patients with relapsed/refractory symptomatic multiple myeloma (MM)
-
2025-521113-13-00
10
Early Parkinson’s Disease
-
2025-521199-80-00
4
Patients with previously untreated symptomatic chronic lymphocytic leu
-
2025-521317-50-00
5
Cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs)
-
2025-521619-37-00
5
Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
-
2025-521696-31-00
6
HR+, HER2- breast cancer at high risk of recurrence
-
2025-521769-29-00
5
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2025-522167-15-00
5
Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
-
2025-522475-28-00
5
Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
-
2025-522801-39-00
4
Stage III Non Small Cell Lung Cancer
-
2025-522817-50-00
6
Severe pain
-
2025-522904-26-00
3
Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephri
-
2025-522983-33-00
5
Chronic rhinosinusitis with nasal polyps
-
2025-523094-42-00
5
Hirschsprung's disease
-
2025-523285-25-00
5
Relapsed or Refractory Multiple Myeloma
-
2025-523555-66-00
5
Myelofibrosis
-
2025-523735-19-00
5
Metastatic Microsatellite Stable Colorectal Cancer